<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7441224\results\search\disease\results.xml">
  <result pre="from 2009 http://orcid.org/0000-0002-3948-0756RojekAmanda M.amanda.rojek@mh.org.auamanda.rojek@unimelb.edu.au123MartinGenevieve E.4HorbyPeter W.peter.horby@ndm.ox.ac.uk1[1], grid.4991.50000 0004 1936 8948Epidemic" exact="Diseases" post="Research Group Oxford (ERGO), Centre for Tropical Medicine and"/>
  <result pre="Melbourne, [4], grid.1623.60000 0004 0432 511XDepartment of Allergy, Immunology and" exact="Respiratory" post="Medicine, The Alfred Hospital, epub: 2020-8-8pmc-release: 2020-8-8collection: 202018265received: 2020-5-11accepted:"/>
  <result pre="a credit line to the data. Abstract Background New emerging" exact="infections" post="have no known treatment. Assessing potential drugs for safety"/>
  <result pre="review Funding http://dx.doi.org/10.13039/100004440Wellcome Trust 107834/Z/15/Z106491/Z/14/ZHorbyPeter W. Funding http://dx.doi.org/10.13039/501100000697Rhodes Scholarships Background" exact="Viral" post="pandemics constitute a major threat to global health security."/>
  <result pre="20â€‰years, we have also seen the emergence of zoonotic human" exact="respiratory" post="coronaviruses with pandemic potential. These have been severe acute"/>
  <result pre="human respiratory coronaviruses with pandemic potential. These have been severe" exact="acute" post="respiratory virus (SARS; caused by SARS-CoV-1), Middle East respiratory"/>
  <result pre="respiratory coronaviruses with pandemic potential. These have been severe acute" exact="respiratory" post="virus (SARS; caused by SARS-CoV-1), Middle East respiratory syndrome"/>
  <result pre="severe acute respiratory virus (SARS; caused by SARS-CoV-1), Middle East" exact="respiratory" post="syndrome (MERS) and, currently, coronavirus disease 2019 (COVID-19) (caused"/>
  <result pre="acute respiratory virus (SARS; caused by SARS-CoV-1), Middle East respiratory" exact="syndrome" post="(MERS) and, currently, coronavirus disease 2019 (COVID-19) (caused by"/>
  <result pre="by SARS-CoV-1), Middle East respiratory syndrome (MERS) and, currently, coronavirus" exact="disease" post="2019 (COVID-19) (caused by SARS-CoV-2) [1]. A study of"/>
  <result pre="the 2009 H1N1 strain influenza A (A(H1N1)pdm09) pandemic, the largest" exact="respiratory" post="viral outbreak in recent years, can provide insights into"/>
  <result pre="2009 H1N1 strain influenza A (A(H1N1)pdm09) pandemic, the largest respiratory" exact="viral" post="outbreak in recent years, can provide insights into the"/>
  <result pre="pandemic mitigation is prophylaxis and treatment of patients. For emerging" exact="viral" post="infections, antiviral therapies are a key medical countermeasure because"/>
  <result pre="objectives listed in TableÂ 1). This review is not only" exact="limited" post="to completed clinical trials, but also includes registered trials"/>
  <result pre="of evidence available Document the time taken to initiate and" exact="complete" post="this clinical research and compare this to the outbreak"/>
  <result pre="abundant. We included research that described hospitalised patients and reported" exact="acute" post="clinical outcomes (defined as the length of hospitalisation, intensive"/>
  <result pre="papers included, two are interventional trials (nâ€‰=â€‰73, representing 0.2% of" exact="total" post="reported patients), [6, 7] 28 are prospective observational studies"/>
  <result pre="28 are prospective observational studies (nâ€‰=â€‰6102, accounting for 15.4% of" exact="total" post="patients), 129 are retrospective observational studies or case reports"/>
  <result pre="are retrospective observational studies or case reports (nâ€‰=â€‰33,342, 84.2% of" exact="total" post="patients) and one enrolled patients both prospectively and retrospectively"/>
  <result pre="for hospitalised patients Treatment name Number of publications reporting use" exact="Total" post="number of patients receiving treatment1 Median (IQR) number of"/>
  <result pre="influenza in 2009 Oseltamivir 154 31,737 63 (21â€&quot;188) Approved for" exact="acute" post="uncomplicated influenza, expanded under EUA April 2009 Zanamivir 54"/>
  <result pre="EUA April 2009 Zanamivir 54 368 2 (1â€&quot;9) Approved for" exact="acute" post="uncomplicated influenza, expanded under EUA April 2009 Peramivir 14"/>
  <result pre="EUA October 2009 Amantadine 11 86 3 (1â€&quot;13) Approved for" exact="acute" post="uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated Rimantadine 5"/>
  <result pre="to A(H1N1)pdm09 demonstrated Rimantadine 5 32 3 (1â€&quot;13) Approved for" exact="acute" post="uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated Ribavirin 5"/>
  <result pre="to first patient enrolment since the identification of the pandemic" exact="viral" post="strain (April 1, 2009) for prospective observational studies was"/>
  <result pre="enrolment stopped a median of 274 (IQR 195â€&quot;313) days after" exact="viral" post="identification. This was 223â€‰days before the PHEIC ended (August"/>
  <result pre="studies (2 with treatment efficacy outcomes, and 3 with general" exact="acute" post="clinical outcomes) planned during the pandemic. A total of"/>
  <result pre="with general acute clinical outcomes) planned during the pandemic. A" exact="total" post="of eight different treatments were to be studied: oseltamivir,"/>
  <result pre="studies Registration number Type of study Treatment Planned enrolment (n)" exact="Total" post="patients1 (n) H1N1 patients1 (n) First patient enrolment1 (month,"/>
  <result pre="Discussion There is consistent criticism that the research response to" exact="disease" post="outbreaks is fractured and delayed [13â€&quot;15]. There has, however,"/>
  <result pre="research [18]. Using this approach, multiple treatments (or even multiple" exact="respiratory" post="viruses) can be evaluated under an overarching protocol and"/>
  <result pre="here from 2009 support the need for this approach to" exact="respiratory" post="virus pandemics, including COVID-19. Indeed, two large platform trials"/>
  <result pre="pre-approved protocols can lay dormant, waiting for cases of pandemic" exact="respiratory" post="viruses, and allow prior assessment of the logistics and"/>
  <result pre="An example of this type of protocol exists for severe" exact="acute" post="respiratory infections (NCT02498587) and has been used to rapidly"/>
  <result pre="example of this type of protocol exists for severe acute" exact="respiratory" post="infections (NCT02498587) and has been used to rapidly enrol"/>
  <result pre="of this type of protocol exists for severe acute respiratory" exact="infections" post="(NCT02498587) and has been used to rapidly enrol patients"/>
  <result pre="rapidly enrol patients with COVID-19. Recommendations following the Ebola virus" exact="disease" post="(EVD) epidemic in West Africa suggest that clinical research"/>
  <result pre="was that large. Beyond the benefits of increased enrolment and" exact="external" post="validity, multicentre research has specific advantages in epidemics. It"/>
  <result pre="the peer-reviewed literature. This is consistent with analyses for other" exact="disease" post="outbreaks, including epidemiology reporting for SARS (where only 7%"/>
  <result pre="variation in what illness severity necessitates hospitalisation which may have" exact="limited" post="the inclusion of studies from countries where care models"/>
  <result pre="that were open during the pandemic period. Abbreviations COVID-19 Coronavirus" exact="disease" post="2019 EVD Ebola virus disease IQR Interquartile range LMICs"/>
  <result pre="pandemic period. Abbreviations COVID-19 Coronavirus disease 2019 EVD Ebola virus" exact="disease" post="IQR Interquartile range LMICs Low- and middle-income countries MERS"/>
  <result pre="Interquartile range LMICs Low- and middle-income countries MERS Middle East" exact="respiratory" post="syndrome NAI Neuraminidase inhibitor PHEIC Public Health Emergency of"/>
  <result pre="range LMICs Low- and middle-income countries MERS Middle East respiratory" exact="syndrome" post="NAI Neuraminidase inhibitor PHEIC Public Health Emergency of International"/>
  <result pre="Neuraminidase inhibitor PHEIC Public Health Emergency of International Concern SARS" exact="Severe" post="acute respiratory virus WHO World Health Organization Publisherâ€™s Note"/>
  <result pre="inhibitor PHEIC Public Health Emergency of International Concern SARS Severe" exact="acute" post="respiratory virus WHO World Health Organization Publisherâ€™s Note Springer"/>
  <result pre="PHEIC Public Health Emergency of International Concern SARS Severe acute" exact="respiratory" post="virus WHO World Health Organization Publisherâ€™s Note Springer Nature"/>
  <result pre="UK. References References 1.ZhuNZhangDWangWLiXYangBSongJet al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med2020382872773310.1056/NEJMoa200101731978945 2.DobsonJWhitleyRJPocockSMontoASOseltamivir treatment for"/>
  <result pre="sirolimus, and steroids improves outcomes in patients with severe H1N1" exact="pneumonia" post="and acute respiratory failureCrit Care Med201442231332110.1097/CCM.0b013e3182a2727d24105455 8.collab: South East"/>
  <result pre="steroids improves outcomes in patients with severe H1N1 pneumonia and" exact="acute" post="respiratory failureCrit Care Med201442231332110.1097/CCM.0b013e3182a2727d24105455 8.collab: South East Asia Infectious"/>
  <result pre="improves outcomes in patients with severe H1N1 pneumonia and acute" exact="respiratory" post="failureCrit Care Med201442231332110.1097/CCM.0b013e3182a2727d24105455 8.collab: South East Asia Infectious Disease"/>
  <result pre="and acute respiratory failureCrit Care Med201442231332110.1097/CCM.0b013e3182a2727d24105455 8.collab: South East Asia" exact="Infectious" post="Disease Clinical Research NEffect of double dose oseltamivir on"/>
  <result pre="acute respiratory failureCrit Care Med201442231332110.1097/CCM.0b013e3182a2727d24105455 8.collab: South East Asia Infectious" exact="Disease" post="Clinical Research NEffect of double dose oseltamivir on clinical"/>
  <result pre="children and adults admitted to hospital with severe influenza: double" exact="blind" post="randomised controlled trialBMJ2013346f303910.1136/bmj.f303923723457 9.KimberlinDWAcostaEPPrichardMNSanchezPJAmpofoKLangDet al.Oseltamivir pharmacokinetics, dosing, and resistance"/>
  <result pre="pandemic influenza researchLancet.200937396812085208610.1016/S0140-6736(09)61131-419541022 15.HaydenFGFarrarJPeirisJSTowards improving clinical management of Middle East" exact="respiratory" post="syndrome coronavirus infectionLancet Infect Dis201414754454610.1016/S1473-3099(14)70793-524964934 16.Grein J, Ohmagari N,"/>
  <result pre="influenza researchLancet.200937396812085208610.1016/S0140-6736(09)61131-419541022 15.HaydenFGFarrarJPeirisJSTowards improving clinical management of Middle East respiratory" exact="syndrome" post="coronavirus infectionLancet Infect Dis201414754454610.1016/S1473-3099(14)70793-524964934 16.Grein J, Ohmagari N, Shin"/>
  <result pre="of conducting a clinical treatment trial during an Ebola virus" exact="disease" post="epidemicClin Infect Dis20186691454145710.1093/cid/cix106129206908 24.Wellcome Trust and The Academy of"/>
  <result pre="Accessed 29 Apr 2020. 25.DunningJKennedySBAntierensAWhiteheadJCigleneckiICarsonGet al.Experimental treatment of Ebola virus" exact="disease" post="with brincidofovirPLoS One2016119e016219910.1371/journal.pone.016219927611077 26.ChengVCChanJFcollab: To KKYuenKYClinical management and infection"/>
  <result pre="virus disease with brincidofovirPLoS One2016119e016219910.1371/journal.pone.016219927611077 26.ChengVCChanJFcollab: To KKYuenKYClinical management and" exact="infection" post="control of SARS: lessons learnedAntivir Res2013100240741910.1016/j.antiviral.2013.08.01623994190 27.KayemNDRojekADenisESalamAReisAOlliaroPet al.Clinical REsearch"/>
 </snippets>
</snippetsTree>
